Recent Advances in Efflux Pump Inhibitors and Their Role in Combatting Multidrug Resistance
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Mechanism and Evolution of Antibiotic Resistance".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 299
Special Issue Editors
Interests: clinical bacteriology; antibiotic resistance; multidrug efflux
Interests: efflux systems of pathogenic bacteria; efflux pump inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antibiotic resistance poses an increasing challenge in modern medicine. Efflux pumps play a crucial role in bacterial resistance by expelling antibiotics out of the cells, thereby reducing their efficacy. Efflux pump inhibitors (EPIs) offer a promising solution to counteract this mechanism, enhancing the effectiveness of existing antibiotics. This Special Issue aims to gather the latest research on EPIs, focusing on molecular mechanisms, novel inhibitors, clinical applications, and resistance patterns.
Efflux pumps contribute significantly to bacterial multidrug resistance via various mechanisms, including biofilm formation and horizontal gene transfer. Recent studies have highlighted novel EPIs and their potential applications:
- New Efflux Systems: A novel major facilitator superfamily (MFS)-type tripartite efflux system, CprABC, was identified in Chryseobacterium PL22-22A, which mediates resistance to polymyxins. The flavonoid compound baicalin showed EPI activity against this system, highlighting new avenues for combatting resistance in Gram-negative bacteria;
- Biofilm Inhibition: Efflux pumps have a dual role in biofilm formation, contributing to both the establishment and maintenance of biofilms. EPIs targeting these pumps have shown effectiveness in disrupting biofilm-related infections, providing new strategies for treating chronic infections associated with medical devices;
- RND Efflux Pump Inhibitors: Synthetic inhibitors targeting RND efflux pumps, such as MexB and AcrB, have demonstrated significant potential in restoring antibiotic efficacy. These inhibitors work by targeting the expression, assembly, or activity of the efflux pump complexes;
- Clinical Applications: EPIs have shown promise in reducing antibiotic resistance in clinical settings. Recent advancements include the development of compounds that enhance the susceptibility of multidrug-resistant bacteria to existing antibiotics, thereby extending the life span of current antimicrobial therapies.
Contributions of Previous Special Issue: The previous Special Issue, "The Role of Efflux Pump Inhibitors in Bacterial Multidrug Resistance", successfully published five articles out of seven submissions. These articles have, collectively, been viewed over 10,000 times and cited 19 times, indicating strong interest and impact in the research community. The first edition published 10 papers, further establishing the importance of this research area.
Research on EPIs remains critical for addressing multidrug-resistant bacterial infections. The findings published in this Special Issue will contribute significantly to the development of new therapeutic strategies and the enhancement of antibiotic efficacy.
Dr. László Orosz
Dr. Spengler Gabriella
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multidrug resistance
- multidrug efflux pump
- efflux pump inhibitor (EPI)
- accumulation assay
- efflux assay
- fluorochromes
- ethidium bromide
- quorum sensing
- biofilm
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
